|
|
| | 1-Piperidinepropanenitrile, α-[(2E)-3-(3,4-dihydroxyphenyl)-2-propen-1-ylidene]-β-oxo-, (αE)- Basic information |
| | 1-Piperidinepropanenitrile, α-[(2E)-3-(3,4-dihydroxyphenyl)-2-propen-1-ylidene]-β-oxo-, (αE)- Chemical Properties |
| Boiling point | 592.8±50.0 °C(predicted) | | density | 1.292±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 9.29±0.10(predicted) |
| | 1-Piperidinepropanenitrile, α-[(2E)-3-(3,4-dihydroxyphenyl)-2-propen-1-ylidene]-β-oxo-, (αE)- Usage And Synthesis |
| Uses | hMAO-B/MB-COMT-IN-2 is a dual MAO-B/MB-COMT inhibitor (IC50s: 4.27 μΜ for hMAO-B, 2.69 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-2 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-2 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD)[1]. | | References | [1] Daniel Chavarria, et al. Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor. Eur J Med Chem. 2022 Sep 8;243:114740. DOI:10.1016/j.ejmech.2022.114740 |
| | 1-Piperidinepropanenitrile, α-[(2E)-3-(3,4-dihydroxyphenyl)-2-propen-1-ylidene]-β-oxo-, (αE)- Preparation Products And Raw materials |
|